Biogenetic Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 2.94 Cr
as on 09-12-2024
- Company Age 20 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 31.43 Cr
as on 09-12-2024
- Satisfied Charges ₹ 26.71 Cr
as on 09-12-2024
- Revenue -1.16%
(FY 2021)
- Profit 118.81%
(FY 2021)
- Ebitda 61.60%
(FY 2021)
- Net Worth 26.64%
(FY 2021)
- Total Assets -17.12%
(FY 2021)
About Biogenetic Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.94 Cr.
The company currently has active open charges totaling ₹31.43 Cr. The company has closed loans amounting to ₹26.71 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mukut Goyal and Vibhor Goyal serve as directors at the Company.
- CIN/LLPIN
U24232RJ2004PTC018909
- Company No.
018909
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- LocationJaipur, Rajasthan
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Biogenetic Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vibhor Goyal  | Director | 21-Jan-2012 | Current |
| Mukut Goyal | Director | 23-Jan-2004 | Current |
Financial Performance of Biogenetic Drugs.
Biogenetic Drugs Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 1.16% decrease. The company also saw a substantial improvement in profitability, with a 118.81% increase in profit. The company's net worth Soared by an impressive increase of 26.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biogenetic Drugs?
In 2023, Biogenetic Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 23 May 2023 | ₹7.25 Cr | Open |
State Bank Of India Creation Date: 30 Oct 2017 | ₹24.18 Cr | Open |
Sidbi Creation Date: 14 Mar 2017 | ₹3.10 Cr | Satisfied |
How Many Employees Work at Biogenetic Drugs?
Unlock and access historical data on people associated with Biogenetic Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biogenetic Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biogenetic Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
